TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Gary Lichtenstein  ¹     Gerhard Rogler  ²     Ala Sharara  ³     Nancy Sunna  ⁴     Rajiv Mundayat  ⁵     Donna T Judd  ⁶     Nervin Lawendy  ⁶     Julian Panés  ^7    
1 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States
² University of Zürich, Zürich, Switzerland
³ American University of Beirut Medical Center, Beirut, Lebanon
⁴ Pfizer, Amman, Jordan
⁵ Pfizer Inc, New York, United States
⁶ Pfizer Inc, Collegeville, United States
⁷ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Topic
IBD

Session
IBD: Clinical trials II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)